Evaxion Completes Phase 2 Trial Extension for Personalized Cancer Vaccine EVX-01
EVAX has more than doubled off its 52-week low of $1.2 on light trading volume (0.3× avg).
Summary
Evaxion A announced the successful completion of the one-year extension of its Phase 2 trial for personalized cancer vaccine EVX-01, with three-year efficacy data expected in the second half of 2026.
Key Events · Product Development and Regulatory · EVAX
-
Phase 2 Trial Extension Completed
Evaxion announced the successful completion of the one-year extension of its Phase 2 trial for the personalized cancer vaccine EVX-01, with the last patient visit now concluded.
-
Three-Year Data Expected H2 2026
Patients will continue to be monitored, and three-year clinical efficacy data from the trial is anticipated to be presented in the second half of 2026.
-
Strong Prior Efficacy Data Reiterated
The company reiterated encouraging one- and two-year data, including a 75% Objective Response Rate and 92% durable clinical benefit at two years, with no relapses observed.
-
AI-Immunology™ Platform Validation
The trial demonstrated EVX-01 induced an immune response in all patients, with 81% of targeted neoantigens generating potent specific T-cell responses, validating the AI-Immunology™ platform.
Analysis · EVAX · Life Sciences
Evaxion A has successfully completed the one-year extension of its Phase 2 trial for the personalized cancer vaccine EVX-01, marking a significant operational milestone. While no new clinical data was released in this filing, the completion of this phase de-risks the trial timeline and sets the stage for the highly anticipated three-year efficacy data, expected in the second half of 2026. The reiteration of strong prior data, including a 75% Objective Response Rate and 92% durable clinical benefit at two years, provides a positive backdrop and validates the company's AI-Immunology™ platform. Investors should monitor for the upcoming data release as the next major catalyst.
At the time of this filing, EVAX was trading at $3.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.1M. The 52-week trading range was $1.20 to $12.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.